October 24, 2016
Astellas’s and Pfizer’s cancer drug gets new product label data
Astellas Pharma and Pfizer have announced the FDA approved a supplemental New …
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 24, 2016
FDA gives green light to Merck’s CDI drug
The US FDA has approved Merck’s Zinplava (bezlotoxumab) Injection 25 mg/mL, which …
October 24, 2016
Biophytis outsources AMD drug production to Patheon, USA
Biophytis has entered into an agreement with US firm Patheon for the industrial …
October 24, 2016
GSK applies to FDA for zoster vaccine
GlaxoSmithKline has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, ShingrixTM, to the United States Food and Drug Administration (FDA).
October 24, 2016
Faron recruits patients for the Japanese Traumakine Phase III trial
Faron Pharmaceuticals (Faron), the clinical stage biopharmaceutical company, has recruited the first patient in the Japanese Phase III pivotal clinical trial for the…
October 21, 2016
Nanobiotix’s partner, PharmaEngine launched a new NBTXR3 clinical trial in head and neck cancers
Nanobiotixa has announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October.
October 21, 2016
Breast Cancer Awareness Month, Roche lists eight signs of breast cancer
October is Breast Cancer Awareness Month, a worldwide annual campaign involving thousands of organizations, to highlight the importance of breast awareness, education and research.
October 21, 2016
Ablynx announces warrant exercise
Ablynx today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 10,050 common shares have been issued by the Company in exchange for EUR47,303 as the result of the exercise of warrants.
October 21, 2016
Anti-inflammatory pills tied to heart failure risk
(Reuters Health) – Widely used non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of heart failure – even in people without a history of cardiac issues, a recent study suggests.
October 21, 2016
Merck’s Keytruda shows success in key bladder cancer trial
Merck announced that the phase 3 keynote-045 trial investigating the use of Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).